NASDAQ : UPC
Universe Pharmaceuticals INC — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · China
Last price 1.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.49M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.39M |
| Enterprise Value | -12.11M |
Dates
| Measure | Value |
|---|
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 5.01M |
| Shares Outstanding | 5.02M |
| Shares Change (YoY) | +205.01% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 88.86% |
| Owned by Institutions (%) | 1.40% |
| Float | 559,871 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.42 |
| Forward PS | n/a |
| PB Ratio | 0.02 |
| P/TBV Ratio | 0.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.05 |
| Quick Ratio | 3.25 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.28 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -3.50% |
| Return on Assets (ROA) | -1.72% |
| Return on Invested Capital (ROIC) | -5.78% |
| Return on Capital Employed (ROCE) | -3.61% |
| Weighted Average Cost of Capital (WACC) | 7.67% |
| Revenue Per Employee | $82,139 |
| Profits Per Employee | -$8,991 |
| Employee Count | 216 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 2.98 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.85 |
| 52-Week Price Change | -68.86% |
| 50-Day Moving Average | 4.15 |
| 200-Day Moving Average | 3.80 |
| Relative Strength Index (RSI) | 22.14 |
| Average Volume (20 Days) | 179,491 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 30,293 |
| Short Previous Month | 43,865 |
| Short % of Shares Out | 0.60% |
| Short % of Float | 5.41% |
| Short Ratio (days to cover) | 0.72 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 17.74M |
| Gross Profit | 6.48M |
| Operating Income | -2.09M |
| Pretax Income | -1.94M |
| Net Income | -1.94M |
| EBITDA | -1.61M |
| EBIT | -2.09M |
| Loss Per Share | -$3.45 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 29.05M |
| Total Debt | 9.55M |
| Net Cash | 19.50M |
| Net Cash Per Share | $3.88 |
| Equity (Book Value) | 55.65M |
| Book Value Per Share | 98.78 |
| Working Capital | 41.56M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.91M |
| Capital Expenditures | -481,019 |
| Depreciation & Amortization | 479,009 |
| Net Borrowing | -6.82M |
| Free Cash Flow | -12.39M |
| FCF Per Share | -$2.47 |
Margins
| Measure | Value |
|---|
| Gross Margin | 36.52% |
| Operating Margin | -11.78% |
| Pretax Margin | -10.95% |
| Profit Margin | -10.95% |
| EBITDA Margin | -9.08% |
| EBIT Margin | -11.78% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -205.01% |
| Shareholder Yield | -205.01% |
| Earnings Yield | -234.40% |
| FCF Yield | -165.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 24, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.67 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |